Vimian Group AB ( ($SE:VIMIAN) ) has shared an announcement.
Vimian Group AB reported a change in its share and vote structure in August following the conversion of 166,405 C shares into an equal number of ordinary shares under the company’s articles of association. This conversion resulted in an increase of 149,764.5 votes, reflecting ongoing adjustments in the company’s capital structure and voting rights.
As of the last trading day in August, Vimian has a total of 533,065,851 shares outstanding, comprising a majority of ordinary shares and several series of C, D and E shares, each with differing voting power. The total number of votes now stands at 527,882,136.3, a change that is relevant for shareholders monitoring ownership influence and corporate governance dynamics.
The detailed breakdown of ordinary and various preference-like share classes, each carrying either full or one-tenth voting rights, underscores the complexity of Vimian’s equity structure. These changes, disclosed under the Financial Instruments Trading Act, help investors track how conversions among share classes may gradually shift voting power and potentially affect future decision-making within the company.
The most recent analyst rating on ($SE:VIMIAN) stock is a Hold
with a SEK35.00 price target.
To see the full list of analyst forecasts on Vimian Group AB stock,
see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB is a global animal health company active in Specialty Pharma, MedTech, Veterinary Services and Diagnostics, focusing on making innovative care accessible to more veterinary professionals and pet owners worldwide. Headquartered in Stockholm, Sweden, it serves over 80 markets, employs about 1,300 people and generates annual revenues of roughly EUR 425 million.
Vimian consolidates pioneering and entrepreneurial businesses to offer advanced products and services for companion and other animals, reinforcing its position in fast-evolving segments of the animal health market. Its broad geographic reach and diversified portfolio aim to capture growing demand for high-quality veterinary care and diagnostic solutions.
The company’s multi-division structure allows it to address different aspects of animal healthcare, from pharmaceuticals and medical devices to clinical services and laboratory diagnostics. This integrated strategy supports Vimian’s ambition to be a leading platform in the animal health industry and deepen its relationships with veterinary clinics and laboratories globally.
YTD Price Performance: 17.67%
Average Trading Volume: 431,372
Technical Sentiment Signal: Buy
Current Market Cap: SEK18.82B
For detailed information about VIMIAN stock, go to TipRanks’ Stock Analysis page.
